The European Commission has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly ...

European Commission says company abused ‘dominant position’ to ‘artificially’ extend patent protection of MS medicine ...

The European Commission announced Thursday it had imposed an antitrust fine exceeding 460 million euros ($500 million) on ...

The European Commission has fined Teva Pharmaceuticals €462.6m for abusing its dominant market position by blocking ...

The European Commission has fined Israeli drugmaker Teva Pharmaceutical Industries (NYSE:TEVA) EUR 462.6M, or around $500M, for trying to ward off competition for its blockbuster multiple sclerosis ...

Some two years after the European Commission accused Teva of meddling with the competition for its former multiple sclerosis blockbuster Copaxone, the other shoe has finally dropped. | The European ...

Teva fined $500 million by EU for misusing patent system to protect its MS drug Copaxone against rival Synthons product.

It had won regulatory approval in Europe for its rival product in 2017, describing it as “therapeutically equivalent” to ...

Today's decision to impose an antitrust fine on Teva for disparagement and misuse of the patent system reaffirms the ...

Teva also allegedly engaged in a “disparagement campaign” against Synthon, the only other company authorized to produce a similar drug in Europe. Teva “spread information contradicted by health ...

Teva Pharmaceuticals disagrees with the European Commission decision, which is based on legal theories that the company believes are extreme, ...